# DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

> **NCT05722886** · PHASE2,PHASE3 · RECRUITING · sponsor: **Cancer Research UK** · enrollment: 825 (estimated)

## Conditions studied

- Haematological Malignancy
- Solid Tumour

## Interventions

- **DRUG:** Alectinib
- **DRUG:** Atezolizumab
- **DRUG:** Entrectinib
- **DRUG:** Trastuzumab in combination with pertuzumab
- **DRUG:** Vemurafenib in combination with cobimetinib
- **DRUG:** Capmatinib

## Key facts

- **NCT ID:** NCT05722886
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 825 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05722886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05722886, "DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05722886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*